Recombinant influenza viruses and uses thereof
| Title: | Recombinant influenza viruses and uses thereof |
|---|---|
| Patent Number: | 9,217,157 |
| Publication Date: | December 22, 2015 |
| Appl. No: | 13/387293 |
| Application Filed: | July 27, 2010 |
| Abstract: | Modified influenza virus NS gene segments and nucleic acid sequences encoding such modified influenza virus NS gene segments are described. In certain embodiments, a modified influenza virus NS gene segment comprises an influenza virus NS 1 open reading frame (ORF) lacking a stop codon, a heterologous nucleotide sequence, a 2A autoproteolytic cleavage site or another cleavage site, an NEP ORF, wherein the gene segment has one or more mutations in either the splice acceptor site, splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA. Also recombinant influenza viruses comprising a modified influenza virus NS gene segment and the use of such viruses are described. The recombinant influenza viruses may be used in the prevention and/or treatment of influenza virus disease or as a delivery vector. |
| Inventors: | Garcia-Sastre, Adolfo (New York, NY, US); Palese, Peter (Loonta, NJ, US); Manicassamy, Balaji (New York, NY, US) |
| Assignees: | Icahn School of Medicine at Mount Sinai (New York, NY, US) |
| Claim: | 1. A pathogenic recombinant influenza virus comprising a nucleic acid sequence comprising a modified influenza virus nonstructural (NS) gene segment or the complement thereof, wherein the modified influenza virus NS gene segment comprises in 3′ to 5′ order: (a) (i) an influenza virus nonstructural protein 1 (NS1) open reading frame (ORF) lacking a stop codon, (ii) a heterologous nucleotide sequence encoding a detectable substance, (iii) a cleavage site, and (iv) an influenza virus nuclear export protein (NEP) ORF, wherein the modified influenza virus NS gene segment has one or more mutations in either the splice acceptor site, the splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA, and wherein the modified influenza virus NS gene segment encodes (1) a fusion protein comprising NS1 and the detectable substance and (2) a protein comprising NEP; or (b) (i) an influenza virus NS1 ORF lacking a stop codon, (ii) a linker, (iii) a heterologous nucleotide sequence encoding a detectable substance, (iv) a cleavage site, and (v) an influenza virus NEP ORF, wherein the modified influenza virus NS gene segment has one or more mutations in either the splice acceptor site, the splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA, and wherein the modified influenza virus NS gene segment encodes (1) a fusion protein comprising NS1, the amino acids encoded by the linker, and the detectable substance, and (2) a protein comprising NEP. |
| Claim: | 2. A recombinant pathogenic influenza virus comprising a nucleic acid sequence comprising a modified influenza virus NS gene segment or the complement thereof, wherein the modified influenza virus NS gene segment comprises in 3′ to 5′ order: (i) an influenza virus NS1 open reading frame (ORF) lacking a stop codon, (ii) a heterologous nucleotide sequence encoding a detectable substance, (iii) a cleavage site, and (iv) an influenza virus NEP ORF, wherein the modified influenza virus NS gene segment has more than one mutation in the splice acceptor site that prevents splicing of mRNA, and wherein the modified influenza virus NS gene segment encodes (1) a fusion protein comprising NS1 and the detectable substance and (2) a protein comprising NEP. |
| Claim: | 3. The recombinant influenza virus of claim 1 , wherein the modified influenza virus comprises an influenza virus NS1 ORF lacking a stop codon, a heterologous nucleotide sequence encoding a detectable substance, a cleavage site, and an influenza virus NEP ORF. |
| Claim: | 4. The recombinant influenza virus of claim 3 , wherein the modified influenza virus NS gene segment further comprises a linker between the heterologous nucleotide sequence encoding a detectable substance and the cleavage site. |
| Claim: | 5. The recombinant influenza virus of claim 1 , wherein the cleavage site is a 2A cleavage site. |
| Claim: | 6. The recombinant influenza virus of claim 5 , wherein the 2A cleavage site is ATNFSLLKQAGDVEENPG P (SEQ ID NO: 20). |
| Claim: | 7. The recombinant influenza virus of claim 2 , wherein the cleavage site is a 2A cleavage site. |
| Claim: | 8. The recombinant influenza virus of claim 7 , wherein the 2A cleavage site is ATNFSLLKQAGDVEENPG P (SEQ ID NO: 20). |
| Claim: | 9. The recombinant influenza virus of claim 1 , wherein the detectable substance is horseradish peroxidase, alkaline phosphatase, beta-galactosidase, acetylcholinesterase, a prosthetic group, strepavidin/biotin, avidin/biotin, luciferase, luciferin, green fluorescent protein, red fluorescent protein, and aequorin. |
| Claim: | 10. The recombinant influenza virus of claim 2 , wherein the detectable substance is horseradish peroxidase, alkaline phosphatase, beta-galactosidase, acetylcholinesterase, a prosthetic group, strepavidin/biotin, avidin/biotin, luciferase, luciferin, green fluorescent protein, red fluorescent protein, and aequorin. |
| Claim: | 11. A DNA encoding the modified NS gene segment of the recombinant influenza virus of claim 1 . |
| Claim: | 12. A DNA encoding the modified NS gene segment of the recombinant influenza virus of claim 2 . |
| Claim: | 13. A substrate comprising the recombinant influenza virus of claim 1 , wherein the substrate comprises isolated host cells or eggs, wherein the eggs are chicken or poultry eggs. |
| Claim: | 14. A substrate comprising the recombinant influenza virus of claim 2 , wherein the substrate comprises isolated host cells or eggs, wherein the eggs are chicken or poultry eggs. |
| Claim: | 15. A pharmaceutical composition comprising the recombinant influenza virus of claim 1 . |
| Claim: | 16. An immunogenic composition comprising the recombinant influenza virus of claim 1 . |
| Claim: | 17. A method for eliciting antibodies against an influenza virus or a heterologous antigen, comprising administering to a non-human subject the immunogenic composition of claim 16 . |
| Claim: | 18. A method for generating a recombinant influenza virus, wherein the method comprises introducing into a host cell the DNA of claim 11 , wherein the host cell expresses all other components for generation of the influenza virus; and purifying the influenza virus from the supernatant of the host cell. |
| Claim: | 19. A method for propagating a recombinant influenza virus, wherein the method comprises infecting a substrate with the recombinant influenza virus of claim 1 and purifying the virus subsequently from the substrate. |
| Claim: | 20. A screening assay to identify a compound that modulates the replication of an influenza virus, comprising: (a) (i) contacting a compound with a host cell infected with the recombinant influenza virus of claim 1 , wherein the recombinant influenza virus expresses the detectable substance, and (ii) measuring the expression or activity of a product encoded by the detectable substance; (b) (i) infecting a host cell with the recombinant influenza virus of claim 1 in the presence of a compound, wherein the recombinant influenza virus expresses the detectable substance, and (ii) measuring the expression or activity of a product encoded by the detectable substance; or (c) (i) contacting a compound with a host cell, (ii) infecting the host cell with the recombinant influenza virus of claim 1 , wherein the recombinant influenza virus expresses the detectable substance, and (iii) measuring the expression or activity of a product encoded by the detectable substance, wherein a compound that increases the replication of influenza virus is identified if the level of expression or activity of the product is increased in the host cell contacted with the compound relative to the level of expression or activity of the product in a host cell contacted with a negative control; and wherein a compound that decreases the replication of influenza virus is identified if the level of expression or activity of the product is decreased in the host cell contacted with the compound relative to the level of expression or activity of the product in a host cell contacted with a negative control. |
| Patent References Cited: | 4693981 September 1987 Wiesehahn et al. 5106619 April 1992 Wiesehahn 5166057 November 1992 Palese et al. 5413923 May 1995 Kucherlapati et al. 5820871 October 1998 Palese et al. 5854037 December 1998 Palese et al. 5891705 April 1999 Budowsky 6001634 December 1999 Palese et al. 6146642 November 2000 Garcia-Sastre et al. 6468544 October 2002 Egorov et al. 6573079 June 2003 Palese et al. 6635246 October 2003 Barrett et al. 6635416 October 2003 Palese et al. 6649372 November 2003 Palese et al. 6669943 December 2003 Palese et al. 6800288 October 2004 Ferko et al. 6852522 February 2005 Palese et al. 6866853 March 2005 Egorov et al. 6887699 May 2005 Palese et al. 6951754 October 2005 Hoffmann 7060430 June 2006 Palese et al. 7312064 December 2007 Hoffmann 7384774 June 2008 Palese et al. 7442527 October 2008 Palese et al. 7494808 February 2009 Palese et al. 7588768 September 2009 Palese et al. 7833774 November 2010 Palese et al. 8057803 November 2011 Palese et al. 8124101 February 2012 Palese et al. 8137676 March 2012 Palese et al. 2009/0203114 August 2009 Palese et al. 2010/0158942 June 2010 Palese et al. 2010/0233785 September 2010 Brandt et al. 2012/0258134 October 2012 Palese et al. 2013/0034581 February 2013 Palese et al. 0 780 475 August 1995 0 702 085 January 2004 WO 87/05331 September 1987 WO 96/34625 November 1996 WO 97/06270 February 1997 WO 97/12032 April 1997 WO 98/02530 January 1998 WO 98/13501 August 1998 WO 98/53078 November 1998 WO 99/02657 January 1999 WO 99/15672 April 1999 WO 99/64068 December 1999 WO 99/64570 December 1999 WO 99/64571 December 1999 WO 01/04333 January 2001 WO 2006/083286 August 2006 WO 2006/088481 August 2006 WO 2007/045674 April 2007 WO 2008/032219 November 2008 WO 2009/007244 January 2009 WO 2009007244 January 2009 |
| Other References: | Basler CF, Reid AH, Dybing JK, Janczewski TA, Fanning TG, Zheng H, Salvatore M, Perdue ML, Swayne DE, Garcia-Sastre A, Palese P, Taubenberger JK. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci U S A. Feb. 27, 2001;98(5):2746-51. cited by examiner Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, Stiegler G, Katinger H, Egorov A. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol. Aug. 2005;79(16):10672-7. cited by examiner Kittel C, Sereinig S, Ferko B, Stasakova J, Romanova J, Wolkerstorfer A, Katinger H, Egorov A. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology. Jun. 20, 2004;324(1):67-73. cited by examiner Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, Vinogradova T, Katinger H, Kiselev O, Egorov A. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol. Aug. 2006;13(8):898-904. cited by examiner Donnelly ML, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D, Ryan MD. The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol. May 2001;82(Pt 5):1027-41. cited by examiner Fernandez-Sesma A, Marukian S, Ebersole BJ, Kaminski D, Park MS, Yuen T, Sealfon SC, Garcia-Sastre A, Moran TM. Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol. Jul. 2006;80(13):6295-304. cited by examiner Zell R, Dauber M, Krumbholz A, Henke A, Birch-Hirschfeld E, Stelzner A, Prager D, Wurm R. Porcine teschoviruses comprise at least eleven distinct serotypes: molecular and evolutionary aspects. J Virol. Feb. 2001;75(4):1620-31; NCBI GenBank Dep. No. AAK12400. cited by examiner Takasuka N, Enami M, Itamura S, Takemori T. Intranasal inoculation of a recombinant influenza virus containing exogenous nucleotides in the NS segment induces mucosal immune response against the exogenous gene product in mice. Vaccine. Feb. 22, 2002;20(11-12):1579-85. cited by examiner Bullido R, Gomez-Puertas P, Saiz MJ, Portela A. Influenza A virus NEP (NS2 protein) downregulates RNA synthesis of model template RNAs. J Virol. May 2001;75(10):4912-7. cited by examiner Baez et al., 1980. Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strains, Nucleic Acids Res. 8(23):5845-58. cited by applicant Basler et al.. 2001, Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci U S A 98(5):2746-2751. cited by applicant Billeter et al., 2009, Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 329:129-162. cited by applicant Briedis et al., 1981. Influenza B virus genome: sequences and structural organization of RNA segment 8 and the mRNAs coding for the NS1 and NS2 proteins. J Virol. 42(1):186-93. cited by applicant Buonagurio et al., 1986. Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. Science 232(47531:980-2. cited by applicant Butterfield et al., 1978, Vaccination for fowl plague. Am J Vet Res. 39(4):671-4. cited by applicant Cheung et al., 2002. Induction of prointlammatory cytokines in human macrophages by influenza A (H5N1), viruses: a mechanism for the unusual severity of human disease? Lancet 360(9348):183I-1837. cited by applicant Cox et al., 2005, Orthomyxoviruses: influenza IN Topley and Wilson's Microbiology and Microbial Infections. London: Hodder Arnold Press, pp. 634-98. cited by applicant De Clercq, 2006, Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5(12):1015-1025. cited by applicant De La Luna et al., 1995. Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs. J Virol 69(4):2427-33. cited by applicant Donnelly et al,. 2001, The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol 82(Pt 5):1027-1041. cited by applicant Egorov et al., 1998. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol. 72(8):6437-41. cited by applicant Egorov et al.. 1997. Generation of influenza A transfectant viruses containing deletions of the carboxyl-terminal part of the NS1 protein. Emergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses. Sep. 21-26, Dublin, Ireland. Abstract No. 108, p. 104. cited by applicant Egorov et al., 1997. Generation of Influenza A Transfectant Viruses Containing Deletions in the NS1 Protein. Institute of Applied Microbiology, Emergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses. Sep. 21-26, Dublin, Ireland. POSTER. cited by applicant Enami et al., 1991. An influenza virus containing nine different RNA segments. Virology 185(I):291-8. cited by applicant Enami et al., 1991, High-efficiency formation of influenza virus transfectants. J Virol. 65(5):2711-3. cited by applicant Enami et al., 1994, Influenza virus NS1 protein stimulates translation of the M1 protein. J Virol. 68(3):1432-7. cited by applicant Ferko et al., 2001, Hyperattenuated Recombinant Influenza A Virus Nonstructural-Protein-Encoding Vectors Induce Human Immunodeficiency Virus Type 1 Nef-Specific Systemic and Mucosal Immune Responses in Mice. J. Virol. 75:8899-908. cited by applicant Ferko et al., 2004, Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. . . J Virol. 78, 23):13037-45. cited by applicant Ferko et al., 2006, Live Attenuated Influenza Virus Expressing Human Interleukin-2 Reveals Increased Immunogenic Potential in Young and Aged Hosts. J. Virol. 80:11621-27. cited by applicant Fesq et al., 1994, Programmed cell death (apoptosis) in human monocytes infected by influenza A virus. Immunobiology 190(1-2):175-182. cited by applicant Fischer et al., 2003. Many cuts to ruin: a comprehensive update of caspase substrates, Cell Death and Differentiation 10:76-100. cited by applicant Flandorfer et al., 2003, Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin. J. Virol. 77:9116-23. cited by applicant Fodor et al., 1999, Rescue of influenza A virus from recombinant DNA, J. Virol. 73:9679-82. cited by applicant Fodor et al., 1998, Attenuation of influenza A virus mRNA levels by promoter mutations. J Virol. 72(8):6283-90. cited by applicant Fortes et al., 1994. Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J. 13(3):704-12. cited by applicant Gao & Palese, 2009, Rewiring the RNAs of influenza virus to prevent reassortment. PNAS 106:15891-96. cited by applicant Gao et al., 2008. A seven-segmented influenza A virus expressing the influenza C virus glycoprotein HEF. Virol 82:6419-26. cited by applicant Garcia-Sastre et al 1998, Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252(2):324-330. cited by applicant Garcia-Sastre et al.. 1994. Introduction of foreign sequences into the genome of influenza A virus. Dev. Biol. Stand. 82:237-246. cited by applicant García-Sastre et al., 1994, Use of a mammalian internal ribosomal entry site element for expression of A foreign protein by a transfectant influenza virus. J. Virol. 68:6254-61. cited by applicant Gazit et al., 2006, Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 7(5):517-523. cited by applicant GenBank database entry CQ867238. cited by applicant GenBank No. AF389122. (GI:21693177). cited by applicant GenBank No. Z21498: GI: 296585. cited by applicant Gibbs et al., 2003, The influenza A virus PBI-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J. Virol. 77:7214-24. cited by applicant Hale et al., 2008, The multifunctional NS1 protein of influenza A viruses. J Gen Virol 89:2359-76. cited by applicant Hao et al., 2008, Differential response of respiratory dendritic cell subsets to influenza virus infection. J Virol 82(10):4908-4919. cited by applicant Hayden & Pavia, 2006, Antiviral management of seasonal and pandemic influenza. J Infect Dis 194 Suppl 2:S119-126. cited by applicant Haye et al., 2009, The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells. J Virol 83(13):6849-6862. cited by applicant Hoffmann et al., 2000, A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 97(11):6108-13. cited by applicant Ibricevic et al., 2006. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol 80(15):7469-7480. cited by applicant Ilyushina, 2007, Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12:363-70. cited by applicant Jin et al,. 2003. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6160. Virology 306:18-24. cited by applicant Kim & Braciale, 2009, Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8+ T cell responses. PLoS One 4(1):e4204. cited by applicant Kittel et al., 2004. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology 324: 67-73. cited by applicant Kittel et al., 2005, Generation of an Influenza A Virus Vector Expressing Biologically Active Human Interleukin-2 from the NS Gene Segment, J. Virol. 79:10672-7. cited by applicant Knipe, 2007, Field's Virology 5th Ed; Orthomyxoviruses. cited by applicant Kochs et al., 2007, Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol 81(13):7011-7021. cited by applicant Koudstaal, et al., 2009, Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 27:2588-93. cited by applicant Krug, 1995. Chapter 8. Unique Functions of the NS1 Protein Textbook of Influenza, Nicholson et al. (eds.), pp. 82-92. cited by applicant Krystal, et al., 1983, Sequential mutations in the NS genes of influenza virus field strains. in J. Virol.; 45, 2):547-54. cited by applicant Kumlin, et al., 2008. Sialic acid tissue distribution and influenza virus tropism. Influenza Other Respi Viruses 2:147-54. cited by applicant Li et al., 1999, Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J. Infect. Dis. 179:1132-38. cited by applicant Lopez et al., 2000, A mouse model for immunization with ex vivo virus-infected dendritic cells. Cell Immunol 206(2):107-115. cited by applicant Lowen et al., 2006, The guinea pig as a transmission model for human influenza viruses. PNAS 103: 9988-92. cited by applicant Manicassamy et al., 2010, Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A 107:11531-6. cited by applicant Marion et al., 1997, the N-terminal half of influenza virus NS1 protein is fully active both in mRNA nuclear retention and enhancement of translation. in Emergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses., Dublin, Ireland. Abstract No. 240, p. 170. cited by applicant Marion et al., 1997, The N-terminal half of the influenza virus Nsi protein is sufficient for nuclear retention of mRNA and enhancement of viral mRNA translation. Nucleic Acids Res. 25(21):4271-7. cited by applicant Marsh et al.. 2008, Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. J Virol 82:2295-304. cited by applicant McGill et al., 2009 Innate immune control and regulation of influenza virus infections. J Leukoc Biol 86(4):803-812. cited by applicant Muramoto et al., 2006, Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J Virol 80:2318-25. cited by applicant Nakaya et al., 2001 Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75:11868-11873. cited by applicant Neumann et al., 1999, Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96:9345-50. cited by applicant Neumann & Kawaoka, 2006, Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 12:881-6. cited by applicant Norton et al.. 1987, Infectious influenza A and B virus variants with long carboxyl terminal deletions in the NS1 polypeptides Virology 156, 2):204 13. cited by applicant O'Neill et al., 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J 17:288-96. cited by applicant Palese et al.. 1999, Learning from our foes: a novel vaccine concept for influenza virus. Arch Virol Suppl. 15:131-8. cited by applicant Palese & Shaw, 2007, Orthomyxoviridae: the viruses and their replication, in Howley, ed., Fields Virology, 5th Edition, Philadelphia, PA: Lippincott Williams & Wilkins, pp. 1647-1689. cited by applicant Parvin et al., 1983, Nonsense mutations affecting the lengths of the NS1 nonstructural proteins of influenza A virus isolates Virology 128(2):512-17. cited by applicant Pekosz et al., 2009, Sialic acid recognition is a key determinant of influenza A virus tropism in murine trachea epithelial cell cultures. Virology 386(1):61-67. cited by applicant Perrone et al., 2008, H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 4(8):e1000115. cited by applicant Pielak et al., 2009, Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A 106(18):7379-7384. cited by applicant Pleschka et al., 1996, A plasmid based reverse genetics system for influenza A virus. J Virol. 70(6):4188-92. cited by applicant Qian et al., 1995, An amino-terminal polypeptide fragment of the influenza virus NS1 protein possesses specific RNA-binding activity and largely helical backbone structure. . . RNA 1:948-56. cited by applicant Quinlivan et al., 2005, Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol 79(13):8431-8439. cited by applicant Reed & Muench. 1938, A simple method of estimating fifty per cent endpoints. The American Journal of Hygiene 27(3):493-497. cited by applicant Richt & Garcia-Sastre, 2009. Attenuated influenza virus vaccines with modified NS1 proteins, Current Topics in Microbiology and Immunology 333:177-195. cited by applicant Schickli et al., 2001 Plasmid-only rescue of influenza A virus vaccine candidates. Philos Trans R Soc Lond B Biol Sci 356:1965-73. cited by applicant Scull et al., 2009, Avian Influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. PLoS Pathog 5(5):e1000424. cited by applicant Seo et al., 2004, No apoptotic deaths and different levels of inductions of inflammatory cytokines in alveolar macrophages infected with influenza viruses. Virology 329(2):270-279. cited by applicant Sereinig et al., 2006, Influenza Virus NS Vectors Expressing the Mycobacterium tuberculosis ESAT-6 Protein Induce CD4+ Th1 Immune Response and Protect Animals against Tuberculosis Challenge. Clinical and Vaccine Immunology 13:898-904. cited by applicant Shinya et al., 2006, Avian flu: influenza virus receptors in the human airway. Nature 440(7083):435-436. cited by applicant Steel et al., 2008, A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine 26:522-31. cited by applicant Stasakova et al.. 2005, Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1β and 18. J. Gen. Virol. 85:185-95. cited by applicant Sugrue et al., 2008. Antiviral drugs for the control of pandemic influenza virus. Ann Acad Med Singapore 37(6):518-524. cited by applicant Talon et al., 2000, Influenza A and B viruses expressing altered NS1 proteins: A vaccine Approach. Proc Natl Acad Sci USA 96(8):4309-14. cited by applicant Tobita et al., 1990, Nucleotide sequence and some biological properties of the NS gene of a newly isolated influenza B virus mutant which has a long carboxyl terminal deletion in the NS1 protein. Virology 174(1):314-9. cited by applicant Tumpey et al.. 2002, Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 99(21):13849-13854. cited by applicant Tumpey et al., 2004, Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 101(9):3166-3171. cited by applicant Tumpey et al., 2005. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 79(23):14933-14944. cited by applicant Tumpey et al., 2000, Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 74(13):6105-6116. cited by applicant Van Riel et al., 2006 H5N1 Virus Attachment to Lower Respiratory Tract. Science 312(5772):399. cited by applicant Vincent et al., 2007, Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine. 25:7990-8009. cited by applicant Von Itzstein, 2007. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6(12):967-974. cited by applicant Wang et al., 2002, Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol. Dec:76(24):12951-62. cited by applicant Wang & Duke. 2007. Cloning of the canine RNA polymerase 1 promoter and establishment of reverse genetics for influenza A and E3 in MDCK cells. Virol. J. 4:102. cited by applicant Watanabe et al., 2008, Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J. Virol. 82(5): 2486-2492. cited by applicant Yannarell et al., 1997 Factors affecting the yield of cold-adapted influenza virus vaccine. J Virol Methods. 64 (2):161-9. cited by applicant Yoshida et al., 1981, Characterization of the RNA Associated with Influenza A Cytoplasmic Inclusions and the Interaction of NS1 Protein with RNA. . . Virology 110:87-97. cited by applicant Young et al. 1983, Efficient Expression of Influenza Virus NS1. Proc. Natl. Acad. Sci. 80:6105-9. cited by applicant Hashimoto et al., 2007, Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol 178(4):2448-2457. cited by applicant Goodpasture et al., 1934, The cultivation of vaccine and other viruses in the chorioallantoic membrane of chick embryos. Science 74(1919):371-2. cited by applicant De Felipe et al., 2006, E unum pluribus: multiple proteins from a self-processing polyprotein. Trends in Biotechnology 24(2): 68-75. cited by applicant |
| Assistant Examiner: | Gill, Rachel |
| Primary Examiner: | Blumel, Benjamin P |
| Attorney, Agent or Firm: | Jones Day |
| Accession Number: | edspgr.09217157 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|